|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Adenosine#Clinical Studies]] |
| | |
| {{Adenosine}}
| |
| | |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Clinical Trial Results==
| |
| | |
| In controlled studies in the United States, bolus doses of 3, 6, 9, and 12 mg were studied. A cumulative 60% of patients with paroxysmal [[supraventricular tachycardia]] had converted to normal sinus rhythm within one minute after an intravenous bolus dose of 6 mg Adenocard (some converted on 3 mg and failures were given 6 mg), and a cumulative 92% converted after a bolus dose of 12 mg. Seven to sixteen percent of patients converted after 1-4 placebo bolus injections. Similar responses were seen in a variety of patient subsets, including those using or not using digoxin, those with Wolff-Parkinson-White Syndrome, males, females, blacks, Caucasians, and Hispanics.
| |
| | |
| Adenosine is not effective in converting rhythms other than PSVT, such as [[atrial flutter]], [[atrial fibrillation]], or [[ventricular tachycardia]], to normal sinus rhythm.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ADENOCARD (ADENOSINE) SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0e32589-dad9-4887-8481-bcf7f6618466 | publisher = | date = | accessdate = }}</ref> | |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Drugs]]
| |
| | |
| [[Category:Antiarrhythmic agents]]
| |